Skip to main content

SYD985 FDA Approval Status

FDA Approved: No
Brand name: SYD985
Generic name: [vic-]trastuzumab duocarmazine
Company: Byondis B.V.
Treatment for: Breast Cancer, Metastatic

SYD985 ([vic-]trastuzumab duocarmazine) is an investigational next generation anti-HER2 antibody-drug conjugate (ADC) in development for the treatment of HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).

Development timeline for SYD985

Jul 12, 2022FDA Accepts Byondis’ Biologics License Application for [Vic-]Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.